According to the Guojin Securities Research Report, the 2026 WCLC was held in Seoul, and innovative Chinese drugs were introduced intensively: Kangfang Iwasi's first-line NSCLC head-to-head Pabolizol, leading IO2.0 with PD-1/VEGF dual antibodies; Hanson/Yilian B7-H3 ADC entered the conference hall, and ADC migrated to the frontline + perioperative period; precision treatments such as KRAS G12D, HER2, and EGFR drug resistance broke through. China's dual antibody/ADC/small nucleic acid has global competitiveness and is leading the world in data. It is expected to catalyze a new round of overseas marketing of innovative drugs and revaluation.

According to the Guojin Securities Research Report, the 2026 WCLC was held in Seoul, and innovative Chinese drugs were introduced intensively: Kangfang Iwasi's first-line NSCLC head-to-head Pabolizol, leading IO2.0 with PD-1/VEGF dual antibodies; Hanson/Yilian B7-H3 ADC entered the conference hall, and ADC migrated to the frontline + perioperative period; precision treatments such as KRAS G12D, HER2, and EGFR drug resistance broke through. China's dual antibody/ADC/small nucleic acid has global competitiveness and is leading the world in data. It is expected to catalyze a new round of overseas marketing of innovative drugs and revaluation.